3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Dermatologic
2
Breast
2
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Melanoma
12
Colorectal Neoplasms
8
Lung Neoplasms
7
Ovarian Neoplasms
6
Neoplasms
5
Mesothelioma, Malignant
5
Carcinoma, Renal Cell
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Pleural Effusion, Malignant
2
Lymphoma
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Adenocarcinoma of Lung
2
Uveal Melanoma
1
Interventions
pembrolizumab
26
Nivolumab
10
Docetaxel
8
avelumab
7
atezolizumab
7
Gemcitabine
7
Carboplatin
6
Trastuzumab
5
Ipilimumab
5
Radiosurgery
4
Psychiatric Rehabilitation
4
Immunoglobulin G
4
Early Intervention, Educational
4
Cyclophosphamide
4
fludarabine
3
durvalumab
3
cemiplimab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Disulfides
3
Counseling
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
utomilumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Interleukin-2
×
Thoracic
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled